ArticleFrontiers in bioengineering and biotechnology2020
Identification of Pan-Cancer Prognostic Biomarkers Through Integration of Multi-Omics Data.
Article in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- Machine Learning-Based Identification of Candidate Serum miRNA Features for Pan-Cancer and Cancer Type Classification.Life (Basel, Switzerland) · 2026Article
- ZRANB1 depletion inhibits neuroblastoma progression by destabilizing MYCN through EZH2-mediated deubiquitination.Cell biology and toxicology · 2026Article
- Integrative Analyses of Individual Patient Genomic-Data to Discover Novel Biomarkers: Application to Cervical Pre-Cancer DNA-Methylation Datasets.Cancer informatics · 2026Article
- Multi-omics prognostic marker discovery and survival modelling: a case study on multi-cancer survival analysis of women's specific tumours.Scientific reports · 2025Article
- TMEM138: From Biological Functions to Diseases.Physiological research · 2025Review
- Genome-wide CRISPR screen identifies BUB1 kinase as a druggable vulnerability in malignant pleural mesothelioma.Cell death & disease · 2025Article
- Senescence-associated secretory phenotype in lung cancer: remodeling the tumor microenvironment for metastasis and immune suppression.Frontiers in oncology · 2025Review
- Single-cell spatial transcriptomics reveals a dystrophic trajectory following a developmental bifurcation of myoblast cell fates in facioscapulohumeral muscular dystrophy.Genome research · 2024Article
- Molecular Subtyping and Survival Analysis of Osteosarcoma Reveals Prognostic Biomarkers and Key Canonical Pathways.Cancers · 2023Article
- Identification of prognostic and predictive biomarkers in high-dimensional data with PPLasso.BMC bioinformatics · 2023Article
- The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis.Antioxidants (Basel, Switzerland) · 2022Review
- Prognostic/predictive markers in systemic therapy resistance and metastasis in breast cancer.Therapeutic advances in medical oncology · 2022Review
- Prognostic Biomarker-Based Identification of Drugs for Managing the Treatment of Endometrial Cancer.Molecular diagnosis & therapy · 2021Article
- Integrative omics analysis reveals effective stratification and potential prognosis markers of pan-gastrointestinal cancers.iScience · 2021Article
- A cell-to-patient machine learning transfer approach uncovers novel basal-like breast cancer prognostic markers amongst alternative splice variants.BMC biology · 2021Article
- Prognostic biomarkers for predicting papillary thyroid carcinoma patients at high risk using nine genes of apoptotic pathway.PloS one · 2021Article
- Integrative Analysis of Identifying Methylation-Driven Genes Signature Predicts Prognosis in Colorectal Carcinoma.Frontiers in oncology · 2021Article
- Recent advances of GOLM1 in hepatocellular carcinoma.Hepatic oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prognostic biomarkers dedicating to treat cancer are very difficult to identify. Although high-throughput sequencing technology allows us to mine prognostic biomarkers much deeper by analyzing omics data, there is lack of effective methods to comprehensively utilize multi-omics data. In this work, we integrated multi-omics data [DNA methylation (DM), gene expression (GE), somatic copy number alternation, and microRNA expression (ME)] and proposed a method to rank genes by desiring a "Score." Applying the method, cancer-specific prognostic biomarkers for 13 cancers were obtained. The prognostic powers of the biomarkers were further assessed by C-indexes (ranged from 0.76 to 0.96). Moreover, by comparing the 13 survival-related gene lists, seven genes (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.